IQVIA Holdings/$IQV
1D1W1MYTD1Y5YMAX
Capital at risk
About IQVIA Holdings
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
- Ticker
- $IQV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 94,000
- Headquarters
- Durham, United States
- Website
- www.iqvia.com
IQVIA Holdings Metrics
BasicAdvanced
$44B
32.89
$8.08
1.19
-
Price and volume
Market cap
$44B
Beta
1.19
52-week high
$271.80
52-week low
$154.50
Average daily volume
1.3M
Financial strength
Current ratio
0.706
Quick ratio
0.62
Long term debt to equity
2.213
Total debt to equity
2.58
Interest coverage (TTM)
3.07%
Profitability
EBITDA (TTM)
3,048
Gross margin (TTM)
32.97%
Net profit margin (TTM)
8.10%
Operating margin (TTM)
13.95%
Effective tax rate (TTM)
15.55%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
5.06%
Return on equity (TTM)
22.82%
Valuation
Price to earnings (TTM)
32.893
Price to revenue (TTM)
2.638
Price to book
7.09
Price to tangible book (TTM)
-2.88
Price to free cash flow (TTM)
20.515
Free cash flow yield (TTM)
4.87%
Free cash flow per share (TTM)
12.95
Growth
Revenue change (TTM)
8.17%
Earnings per share change (TTM)
16.67%
3-year revenue growth (CAGR)
4.98%
10-year revenue growth (CAGR)
14.21%
3-year earnings per share growth (CAGR)
11.57%
10-year earnings per share growth (CAGR)
9.28%
What the Analysts think about IQVIA Holdings
Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.
Analyst projections of the future price of IQVIA Holdings stock.
Bulls say / Bears say
IQVIA delivered second-quarter 2026 revenue of $4.368 billion (up 8.7% year-over-year) and Adjusted EBITDA of $994 million (up 9.2% year-over-year), prompting a raise in full-year guidance to $17.275–17.475 billion in revenue, $4.0–4.05 billion in Adjusted EBITDA, and $12.80–13.00 in Adjusted EPS (SEC EDGAR)
As of June 30, 2026, IQVIA had $2.819 billion remaining under its share repurchase authorization, reflecting strong free cash flow generation and shareholder return capacity (SEC EDGAR)
IQVIA’s agreement to acquire drug discovery assets from Charles River Laboratories, including five specialized in vitro sites and an AI-driven small-molecule platform, expands its end-to-end discovery capabilities and enhances its early-stage R&D service offerings (Business Wire)
IQVIA’s high net leverage of $14.09 billion in net debt and a net leverage ratio of 3.59x trailing twelve-month Adjusted EBITDA could constrain financial flexibility and exacerbate risks amid rising interest rates (SEC EDGAR)
The company factored an approximately 80 basis-point unfavorable foreign exchange impact into its revised guidance, underscoring currency volatility risks that could weigh on revenue growth (SEC EDGAR)
Morgan Stanley downgraded IQVIA to Equal-Weight citing skepticism around margin expansion amid increasing client insourcing of clinical trial workflows, signaling limited upside and valuation headwinds (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Aug 2026.
IQVIA Holdings Financial Performance
Revenues and expenses
IQVIA Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
IQVIA Holdings News
AllArticlesVideos
IQVIA Announces Pricing of Senior Notes
Business Wire5 days ago
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
Business Wire2 weeks ago
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
Business Wire3 weeks ago
Funds containing IQVIA Holdings
AllUSDEURGBP
Fund name | Fund size | $IQV weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.75% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.75% |
iShares Healthcare Innovation£DRDR | £1B | 1.75% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 1.18% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.67% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.